bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S1 from Autofluorescence Imaging to Monitor the Progression of Oral Potentially Malignant Disorders
Authors: Cherry Katelin D. , Schwarz Richard A. , Yang Eric C. , Vohra Imran S. , Badaoui Hawraa , Williams Michelle D. , Vigneswaran Nadarajah , Gillenwater Ann M. , Richards-Kortum Rebecca
Published: April 2023

Figure S1 shows a box and whisker plot visualizing RG Ratios stratified by pathological category.
Supplementary Data from Changes in Dietary Inflammatory Index Patterns with Weight Loss in Women: A Randomized Controlled Trial
Authors: Duggan Catherine , Tapsoba Jean de Dieu , Shivappa Nitin , Harris Holly R. , Hébert James R. , Wang Ching-Yun , McTiernan Anne
Published: April 2023

Supplementary tables
Supplementary Figure S3 from The Role of Lysosome-associated Membrane Protein 2 in Prostate Cancer Chemopreventive Mechanisms of Sulforaphane
Authors: Hahm Eun-Ryeong , Singh Krishna B. , Kim Su-Hyeong , Powolny Anna A. , Singh Shivendra V.
Published: April 2023

Immunoblotting for effect of SFN treatment and/or LAMP2 knockdown on NRF2 protein expression.
Supplementary Data from Oral Health and Risk of Upper Gastrointestinal Cancers in a Large Prospective Study from a High-risk Region: Golestan Cohort Study
Authors: Yano Yukiko , Abnet Christian C. , Poustchi Hossein , Roshandel Gholamreza , Pourshams Akram , Islami Farhad , Khoshnia Masoud , Amiriani Taghi , Norouzi Alireza , Kamangar Farin , Boffetta Paolo , Brennan Paul , Dawsey Sanford M. , Vogtmann Emily , Malekzadeh Reza , Etemadi Arash
Published: April 2023

Supplemental figures and tables
Supplementary Table S3 from Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells In vitro and In vivo
Authors: Castro Nadia P. , Rangel Maria C. , Merchant Anand S. , MacKinnon Gabriel , Cuttitta Frank , Salomon David S. , Kim Young S.
Published: April 2023

Embryonic stem cell and EMT-MET markers selected for the nCounter® Customized Gene Expression Codeset showing differentially expressed genes (p < 0.05) between CTRLs and SFN-treated groups during primary tumor growth
Supplemental Table S1. List of genes significantly deregulated by sedentary activity (P<0.05). from Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression
Authors: Pettapiece-Phillips Rachael , Kotlyar Max , Chehade Rania , Salmena Leonardo , Narod Steven A. , Akbari Mohammad , Jurisica Igor , Kotsopoulos Joanne
Published: April 2023

Supplemental Table S1. List of genes significantly deregulated by sedentary activity (P<0.05).
Supplemental Figure 4. Median BRCA1 mRNA expression (counts) among women with high vs. low mean sedentary time (hours/day). from Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression
Authors: Pettapiece-Phillips Rachael , Kotlyar Max , Chehade Rania , Salmena Leonardo , Narod Steven A. , Akbari Mohammad , Jurisica Igor , Kotsopoulos Joanne
Published: April 2023

Supplemental Figure of median BRCA1 mRNA expression (counts) among women with high vs. low mean sedentary time (hours/day).
Table 1S from Detection and Genotyping of HPV DNA in a Group of Unvaccinated Young Women from Colombia: Baseline Measures Prior to Future Monitoring Program
Authors: Puerto Devi , Reyes Viviana , Lozano Cristina , Buitrago Lina , Garcia Diego , Murillo Raúl H. , Muñoz Nubia , Hernandez Gustavo A. , Sanchez Laura , Wiesner Carolina , Combita Alba L.
Published: April 2023

Association between Asocio-demographic and behavioral sexual characteristics with the HR-HPV infection
Figure 1S from Detection and Genotyping of HPV DNA in a Group of Unvaccinated Young Women from Colombia: Baseline Measures Prior to Future Monitoring Program
Authors: Puerto Devi , Reyes Viviana , Lozano Cristina , Buitrago Lina , Garcia Diego , Murillo Raúl H. , Muñoz Nubia , Hernandez Gustavo A. , Sanchez Laura , Wiesner Carolina , Combita Alba L.
Published: April 2023

Prevalence of HPV infection in preneoplastic lesions according to single or multiple infections
Table S2 from Plasma and Urine Metabolite Profiles Impacted by Increased Dietary Navy Bean Intake in Colorectal Cancer Survivors: A Randomized-Controlled Trial
Authors: Zarei Iman , Baxter Bridget A. , Oppel Renee C. , Borresen Erica C. , Brown Regina J. , Ryan Elizabeth P.
Published: April 2023

Supplementary Table 2
Supplementary Table from Sociocultural Factors, Access to Healthcare, and Lifestyle: Multifactorial Indicators in Association with Colorectal Cancer Risk
Authors: Warren Andersen Shaneda , Zheng Wei , Steinwandel Mark , Murff Harvey J. , Lipworth Loren , Blot William J.
Published: April 2023

Supplementary Table from Sociocultural Factors, Access to Healthcare, and Lifestyle: Multifactorial Indicators in Association with Colorectal Cancer Risk
Supplementary Table S1 from The Relationship Between Breast Density Change During Menopause and the Risk of Breast Cancer in Korean Women
Authors: Kang Danbee , Kim Ji-Yeon , Kim Ji-Young , Mun Han Song , Yoon Sook Ja , Lee Jieun , Han Gayeon , Im Young-Hyuck , Shin Soo-Young , Lee Se Kyung , Yu Jong-Han , Lee Kyung-Hyun , Kim Mincheol , Park Dohyun , Choi Yoon-Ho , Jeong Ok Soon , Lee Jean Hyoung , Jekal Se Yong , Choi Jong Soo , Guallar Eliseo , Chang Yoosoo , Ryu Seungho , Cho Juhee , Kang Mira
Published: April 2023

Hazard ratio for incidence of breast cancer by breast density premenopause
SupplementaryFigures 1-4 from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype
Authors: Kanth Priyanka , Bronner Mary P. , Boucher Kenneth M. , Burt Randall W. , Neklason Deborah W. , Hagedorn Curt H. , Delker Don A.
Published: April 2023

Suppl Fig 1 - Diagram of 2-fold differentially expressed genes in polyps Suppl Fig 2 - Heatmap of differentially expressed genes in uninvolved colon Suppl Fig 3 - Heatmap of microarray data Suppl Fig 4 - qPCR validation
Supplementary Methods from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype
Authors: Kanth Priyanka , Bronner Mary P. , Boucher Kenneth M. , Burt Randall W. , Neklason Deborah W. , Hagedorn Curt H. , Delker Don A.
Published: April 2023

Suppl methods
Figure S6 from Progestin Significantly Inhibits Carcinogenesis in the Mogp-TAg Transgenic Mouse Model of Fallopian Tube Cancer
Authors: Nelson Omar L. , Rosales Rebecca , Turbov Jane M. , Thaete Larry G. , Cline J. Mark , Rodriguez Gustavo C.
Published: April 2023

Figure S6 shows cleaved caspase-3 induction in the mogp-TAg mice.
Supplementary Figures Legends from IKZF1 Gene in Childhood B-cell Precursor Acute Lymphoblastic Leukemia: Interplay between Genetic Susceptibility and Somatic Abnormalities
Authors: Lopes Bruno A. , Barbosa Thayana C. , Souza Bruna K.S. , Poubel Caroline P. , Pombo-de-Oliveira Maria S. , Emerenciano Mariana
Published: April 2023

Supplementary Figures Legends
Table S6 from A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies
Authors: Sroczynski Gaby , Gogollari Artemisa , Kuehne Felicitas , Hallsson Lára R. , Widschwendter Martin , Pashayan Nora , Siebert Uwe
Published: April 2023

Results of cost-effectiveness studies evaluating genetic testing followed by risk-reducing interventions for diagnosed mutation carriers: discounted cost, life years (LY), quality-adjusted life years (QALY), incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR).
Table S5 from A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies
Authors: Sroczynski Gaby , Gogollari Artemisa , Kuehne Felicitas , Hallsson Lára R. , Widschwendter Martin , Pashayan Nora , Siebert Uwe
Published: April 2023

Results of cost-effectiveness studies evaluating risk-reducing intervention strategies in women with different risk profiles: discounted cost, life years (LY), quality-adjusted life years (QALY), incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR).
Table S3 from A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies
Authors: Sroczynski Gaby , Gogollari Artemisa , Kuehne Felicitas , Hallsson Lára R. , Widschwendter Martin , Pashayan Nora , Siebert Uwe
Published: April 2023

Characteristics of the included cost-effectiveness studies evaluating ovarian cancer screening and/or prevention strategies
Supplementary Table 3 from Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice
Authors: Rossi Emily L. , de Angel Rebecca E. , Bowers Laura W. , Khatib Subreen A. , Smith Laura A. , Van Buren Eric , Bhardwaj Priya , Giri Dilip , Estecio Marcos R. , Troester Melissa A. , Hair Brionna Y. , Kirk Erin L. , Gong Ting , Shen Jianjun , Dannenberg Andrew J. , Hursting Stephen D.
Published: April 2023

Mouse Mapping Statistics, n=3/group.
Supplementary Figure 1 from Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice
Authors: Rossi Emily L. , de Angel Rebecca E. , Bowers Laura W. , Khatib Subreen A. , Smith Laura A. , Van Buren Eric , Bhardwaj Priya , Giri Dilip , Estecio Marcos R. , Troester Melissa A. , Hair Brionna Y. , Kirk Erin L. , Gong Ting , Shen Jianjun , Dannenberg Andrew J. , Hursting Stephen D.
Published: April 2023

Regulation of pro-growth and inflammatory gene expression.
Supplementary Figure from Saliva and Lung Microbiome Associations with Electronic Cigarette Use and Smoking
Authors: Ying Kevin L. , Brasky Theodore M. , Freudenheim Jo L. , McElroy Joseph P. , Nickerson Quentin A. , Song Min-Ae , Weng Daniel Y. , Wewers Mark D. , Whiteman Noah B. , Mathe Ewy A. , Shields Peter G.
Published: April 2023

Supplementary Figure from Saliva and Lung Microbiome Associations with Electronic Cigarette Use and Smoking
Supplementary Figure S1 from Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer
Authors: Young Adelaide , Bu Wen , Jiang Weiyu , Ku Amy , Kapali Jyoti , Dhamne Sagar , Qin Lan , Hilsenbeck Susan G. , Du Yi-Chieh Nancy , Li Yi
Published: April 2023

Supplementary Figure S1 shows characterization of PIK3CAH1047R tumors from mice after preventative treatment with venetoclax.
S Table 2 from Physical Activity Plus Energy Restriction Prevents 4T1.2 Mammary Tumor Progression, MDSC Accumulation, and an Immunosuppressive Tumor Microenvironment
Authors: Turbitt William J. , Xu Yitong , Sosnoski Donna M. , Collins Shawntawnee D. , Meng Huicui , Mastro Andrea M. , Rogers Connie J.
Published: April 2023

Comparison of the number of splenocytes and splenic populations among the treatment groups at day 35 post-tumor implantation and when tumor were equal size
Supplemental Table S5 from Effect of Green Tea Supplements on Liver Enzyme Elevation: Results from a Randomized Intervention Study in the United States
Authors: Yu Zheming , Samavat Hamed , Dostal Allison M. , Wang Renwei , Torkelson Carolyn J. , Yang Chung S. , Butler Lesley M. , Kensler Thomas W. , Wu Anna H. , Kurzer Mindy S. , Yuan Jian-Min
Published: April 2023

Supplemental Table S5 demonstrates the change of serum ALT and AST during the intervention period from baseline in subgroups stratified by selected baseline characteristics.
Supplementary Figure S4 from Effects of Walnut Consumption on Colon Carcinogenesis and Microbial Community Structure
Authors: Nakanishi Masako , Chen Yanfei , Qendro Veneta , Miyamoto Shingo , Weinstock Erica , Weinstock George M. , Rosenberg Daniel W.
Published: April 2023

Abundance of OTU clade A through D, G and H.
Supplementary Figure S2 from Effects of Walnut Consumption on Colon Carcinogenesis and Microbial Community Structure
Authors: Nakanishi Masako , Chen Yanfei , Qendro Veneta , Miyamoto Shingo , Weinstock Erica , Weinstock George M. , Rosenberg Daniel W.
Published: April 2023

Number of ACF in Study 2.
Supplementary Table from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer
Authors: Ghosh Jayashri , Schultz Bryant M. , Chan Joe , Wultsch Claudia , Singh Rajveer , Shureiqi Imad , Chow Stephanie , Doymaz Ahmet , Varriano Sophia , Driscoll Melissa , Muse Jennifer , Kleiman Frida E. , Krampis Konstantinos , Issa Jean-Pierre J. , Sapienza Carmen
Published: April 2023

Supplementary Table from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer
Supplementary Data from Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients
Authors: Greenlee Heather , Shi Zaixing , Hibshoosh Hanina , Giri Dilip D. , Ahmed Aqeel , Williams Samantha , Falcone Domenick J. , Winston Lisle A. , Zhou Xi K. , Hudis Clifford A. , Hershman Dawn L. , Dannenberg Andrew J. , Iyengar Neil M.
Published: April 2023

Sup Fig 1
Supplementary Figure from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer
Authors: Ghosh Jayashri , Schultz Bryant M. , Chan Joe , Wultsch Claudia , Singh Rajveer , Shureiqi Imad , Chow Stephanie , Doymaz Ahmet , Varriano Sophia , Driscoll Melissa , Muse Jennifer , Kleiman Frida E. , Krampis Konstantinos , Issa Jean-Pierre J. , Sapienza Carmen
Published: April 2023

Supplementary Figure from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer
Supplementary Figure from Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors
Authors: Singh Krishna B. , Hahm Eun-Ryeong , Kim Su-Hyeong , Singh Shivendra V.
Published: April 2023

Supplementary Figure from Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors
Data from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
Authors: Einstein Mark H. , Roden Richard B.S. , Ferrall Louise , Akin Mark , Blomer Allison , Wu T.C. , Chang Yung-Nien
Published: April 2023

Abstract
Patients with human papillomavirus type 16 (HPV16) infection and low-grade cervical dysplasia [low-grade squamous intraepithelial lesion (LSIL)/CIN1] or atypical squamous cells [atypical squamous cells of undetermined significance (ASC-US)/atypical squamous cells- cannot exclude high-grade squamous intraepithelial lesion (ASC-H)] require active surveillance for disease progression. A safe and effective immunotherapy to clear HPV16 is an unmet medical need. The safety run-in cohort of a randomized double-blind, placebo-controlled phase II trial of PVX2 [vaccination twice with HPV16-targeting pNGVL4a-Sig/E7(detox)/HSP70 plasmid and once with the HPV16 L2E7E6 fusion protein “TA-CIN”] as immunotherapy for patients with HPV16+ ASC-US, ASC-H, or LSIL/CIN1 (NCT03911076) was recently completed. The primary objective of this cohort was to determine the safety and tolerability of PVX2 vaccination. Subjects were confirmed to have HPV16 infection and LSIL/CIN1, ASC-US, or ASC-H. Adverse events were evaluated using Common Terminology Criteria for Adverse Events v5.0. HPV typing by HPV16 18/45 Aptima Assay was done at baseline, month 6, and month 12, with simultaneous cytology analysis. Cervical biopsies and endocervical curettage were performed at baseline and month 6. In the safety run-in cohort 12 eligible patients were enrolled. Each received three monthly immunizations. One was lost to follow-up after week 12. There were no serious adverse events. A total of five adverse events were noted by 4 patients; 4 were considered not vaccine-related, and one ‘unlikely related’ by the investigator. At month 6, 45% (5/11) of participants converted to HPV16-negative and 2 others developed CIN2+ and received a loop electrosurgical excision procedure. At month 12, 64% (7/11) were HPV16-negative, including those HPV16-negative at month 6. In conclusion, PVX2 immunotherapy was well tolerated and associated with viral regression, supporting further testing.
Prevention Relevance:
This safety run-in study cohort suggests that PVX2 immunotherapy is well tolerated in the target population and is sufficiently safe to warrant further clinical testing in a randomized study. The combined vaccines may facilitate higher-than-expected rate of human papillomavirus type 16 viral clearance 6 and 12 months after treatment, although this requires validation.
Data from Curcumin: A Double Hit on Malignant Mesothelioma
Authors: Miller Jill M. , Thompson Joyce K. , MacPherson Maximilian B. , Beuschel Stacie L. , Westbom Catherine M. , Sayan Mutlay , Shukla Arti
Published: April 2023

Abstract
Inflammation is a key mediator in the development of malignant mesothelioma, which has a dismal prognosis and poor therapeutic strategies. Curcumin, a naturally occurring polyphenol in turmeric, has been shown to possess anticarcinogenic properties through its anti-inflammatory effects. Inflammasomes, a component of inflammation, control the activation of caspase-1 leading to pyroptosis and processing of proinflammatory cytokines, interleukin (IL)-1β and IL-18. In the present study, we investigate the role of curcumin in pyroptotic cell death of malignant mesothelioma cells. Using in vitro models with mouse and human malignant mesothelioma cells, curcumin is shown to induce pyroptosis through activation of caspase-1 and increased release of high-mobility group box 1 (HMGB1) without processing of IL-1β and IL-18. Absence of IL-1β processing in response to curcumin-mediated caspase-1 activation is attributed to blockade of pro-IL-1β priming through inhibition of the NF-κB pathway. Furthermore, curcumin's cytotoxicity in malignant mesothelioma cells is demonstrated to be dependent on pyroptosis as inhibition of caspase-1 resulted in protection against curcumin-induced cell death. We also demonstrate that curcumin-mediated caspase-1 activation is oxidant dependent by using N-acetyl-L-cysteine (NAC) to inhibit pyroptosis. PCR array analysis using the human inflammasome template revealed that curcumin significantly downregulated levels of inflammasome-related gene expression involved in inflammation, e.g., NF-κB, toll-like receptors (TLR), and IL-1β. Our data indicate that curcumin has a double effect on malignant mesothelioma cells through induction of pyroptosis while subsequently protecting against inflammation. Cancer Prev Res; 7(3); 330–40. ©2014 AACR.
Data from Serum Glycans as Risk Markers for Non–Small Cell Lung Cancer
Authors: Ruhaak L. Renee , Stroble Carol , Dai Jianliang , Barnett Matt , Taguchi Ayumu , Goodman Gary E. , Miyamoto Suzanne , Gandara David , Feng Ziding , Lebrilla Carlito B. , Hanash Samir
Published: April 2023

Abstract
Previous studies have suggested occurrence of altered serum glycan profiles in patients with lung cancer. Here, we aimed to determine the predictive value of serum glycans to distinguish non–small cell lung cancer (NSCLC) cases from controls in prediagnostic samples using a previously validated predictive protein marker pro-SFTPB, as anchor. Blinded prediagnostic serum samples were obtained from the Carotene and Retinol Efficacy Trial (CARET), and included a discovery set of 100 NSCLC cases and 199 healthy controls. A second test set consisted of 108 cases and 216 controls. Cases and controls were matched for age at baseline (5-year groups), sex, smoking status (current vs. former), study enrollment cohort, and date of blood draw. Serum glycan profiles were determined by mass spectrometry. Twelve glycan variables were identified to have significant discriminatory power between cases and controls in the discovery set (AUC > 0.6). Of these, four were confirmed in the independent validation set. A combination marker yielded AUCs of 0.74 and 0.64 in the discovery and test set, respectively. Four glycan variables exhibited significant incremental value when combined with pro-SFTPB compared with pro-SFTPB alone with AUCs of 0.73, 0.72, 0.72, and 0.72 in the test set, indicating that serum glycan signatures have relevance to risk assessment for NSCLC. Cancer Prev Res; 9(4); 317–23. ©2016 AACR.
Data from The Effect of Mouse Strain, Sex, and Carcinogen Dose on Toxicity and the Development of Lung Dysplasia and Squamous Cell Carcinomas in Mice
Authors: Riolobos Laura , Gad Ekram A. , Treuting Piper M. , Timms Andrew E. , Hershberg Elliot A. , Corulli Lauren R. , Rodmaker Erin , Disis Mary L.
Published: April 2023

Abstract
In order to translate new treatments to the clinic, it is necessary to use animal models that closely recapitulate human disease. Lung cancer develops after extended exposure to carcinogens. It has one of the highest mutation rates of all cancer and is highly heterogenic. Topical treatment with N-nitrosotris-(2-chloroethyl)urea (NTCU) induces lung squamous cell carcinoma (SCC) with nonsynonymous mutation rates similar to those reported for human non–small cell lung cancer. However, NTCU induces lung cancer with variable efficacy and toxicity depending on the mouse strain. A detailed characterization of the NTCU model is needed. We have compared the effect of three different NTCU doses (20, 30, and 40 mmol/L) in female and male of NIH Swiss, Black Swiss, and FVB mice on tumor incidence, survival, and toxicity. The main findings in this study are (1) NIH Swiss mice present with a higher incidence of SCC and lower mortality compared with Black Swiss and FVB mice; (2) 30 mmol/L NTCU dose induces SCC at the same rate and incidence as the 40 mmol/L dose with lower mortality; (3) female mice present higher grade and incidence of preinvasive lesions and SCC compared with males; (4) NTCU-induced transformation is principally within the respiratory system; and (5) NTCU treatment does not affect the ability to elicit a specific adaptive immune response. This study provides a reference point for experimental designs to evaluate either preventive or therapeutic treatments for lung SCC, including immunotherapies, before initiating human clinical trials.
Supplementary Table 1 from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
Authors: Serra Violeta , Vivancos Ana , Puente Xose S. , Felip Enriqueta , Silberschmidt Daniel , Caratù Ginevra , Parra Josep-Lluís , De Mattos-Arruda Leticia , Grueso Judit , Hernández-Losa Javier , Arribas Joaquín , Prudkin Ludmila , Nuciforo Paolo , Scaltriti Maurizio , Seoane Joan , Baselga José
Published: April 2023

Supplementary Table 1 - XLSX 39K, Exome sequencing results. The table contains the raw data for Figure 2B as well as the mutation allele frequency, the prediction of protein functionality, the inclusion in the Cancer Gene Census and the protein function. Sample legend: B, DCIS right; C, DCIS left; D, NSCLC left; E, NSCLC right; F, N2(4R)
Supplementary Figures 1-15, Supplementary Tables 1-2, Supplementary Methods from Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Authors: Beltran Himisha , Rickman David S. , Park Kyung , Chae Sung Suk , Sboner Andrea , MacDonald Theresa Y. , Wang Yuwei , Sheikh Karen L. , Terry Stéphane , Tagawa Scott T. , Dhir Rajiv , Nelson Joel B. , de la Taille Alexandre , Allory Yves , Gerstein Mark B. , Perner Sven , Pienta Kenneth J. , Chinnaiyan Arul M. , Wang Yuzhuo , Collins Colin C. , Gleave Martin E. , Demichelis Francesca , Nanus David M. , Rubin Mark A.
Published: April 2023

PDF file - 4.12MB
Supplementary Figure Legends 1-7, Table Legends 1-9 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Authors: Held Matthew A. , Langdon Casey G. , Platt James T. , Graham-Steed Tisheeka , Liu Zongzhi , Chakraborty Ashok , Bacchiocchi Antonella , Koo Andrew , Haskins Jonathan W. , Bosenberg Marcus W. , Stern David F.
Published: April 2023

PDF file - 84K
Supplementary Table 1 from Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
Authors: Koo Ghee Chong , Tan Soo Yong , Tang Tiffany , Poon Song Ling , Allen George E. , Tan Leonard , Chong Soo Ching , Ong Whee Sze , Tay Kevin , Tao Miriam , Quek Richard , Loong Susan , Yeoh Kheng-Wei , Yap Swee Peng , Lee Kuo Ann , Lim Lay Cheng , Tan Daryl , Goh Christopher , Cutcutache Ioana , Yu Willie , Young Ng Cedric Chuan , Rajasegaran Vikneswari , Heng Hong Lee , Gan Anna , Ong Choon Kiat , Rozen Steve , Tan Patrick , Teh Bin Tean , Lim Soon Thye
Published: April 2023

PDF file - 75K, Sequence analysis summary of tumor and blood samples from four NKTCL cases
Supplementary Figure 4 from Chimeric Transcript Generated by cis-Splicing of Adjacent Genes Regulates Prostate Cancer Cell Proliferation
Authors: Zhang Yanmei , Gong Mei , Yuan Huiling , Park Hong G. , Frierson Henry F. , Li Hui
Published: April 2023

PDF file - 203K, Expression of wild type SLC45A3 and ELK4 in LNCaP cells with CTCF silencing
Supplementary Figure 2 from Chimeric Transcript Generated by cis-Splicing of Adjacent Genes Regulates Prostate Cancer Cell Proliferation
Authors: Zhang Yanmei , Gong Mei , Yuan Huiling , Park Hong G. , Frierson Henry F. , Li Hui
Published: April 2023

PDF file - 175K, Androgen effect on SLC45A3-ELK4 in LNCaP cells
Supplementary Figure 1 from Chimeric Transcript Generated by cis-Splicing of Adjacent Genes Regulates Prostate Cancer Cell Proliferation
Authors: Zhang Yanmei , Gong Mei , Yuan Huiling , Park Hong G. , Frierson Henry F. , Li Hui
Published: April 2023

PDF file - 122K, Expression of SLC45A3-ELK4 chimeric RNA in prostate cells
Supplementary Methods from Bone Marrow–Derived Gr1+ Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1
Authors: Catena Raúl , Bhattacharya Nandita , El Rayes Tina , Wang Suming , Choi Hyejin , Gao Dingcheng , Ryu Seongho , Joshi Natasha , Bielenberg Diane , Lee Sharrell B. , Haukaas Svein A. , Gravdal Karsten , Halvorsen Ole J. , Akslen Lars A. , Watnick Randolph S. , Mittal Vivek
Published: April 2023

Supplementary methods - PDF file 98K, Supplementary methods
Supplementary Figure S12 from Bone Marrow–Derived Gr1+ Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1
Authors: Catena Raúl , Bhattacharya Nandita , El Rayes Tina , Wang Suming , Choi Hyejin , Gao Dingcheng , Ryu Seongho , Joshi Natasha , Bielenberg Diane , Lee Sharrell B. , Haukaas Svein A. , Gravdal Karsten , Halvorsen Ole J. , Akslen Lars A. , Watnick Randolph S. , Mittal Vivek
Published: April 2023

Supplementary Figure S12 - PDF file 118K, Prosaposin mimetic peptide DWLPK upregulates Tsp-1 in tumor-recruited Gr1 cells in the lung
Supplementary Figure Legends 1-9, Table Legends 1-2 from miR-23a Promotes the Transition from Indolent to Invasive Colorectal Cancer
Authors: Jahid Sohail , Sun Jian , Edwards Robert A. , Dizon Diana , Panarelli Nicole C. , Milsom Jeffrey W. , Sikandar Shaheen S. , Gümüş Zeynep H. , Lipkin Steven M.
Published: April 2023

PDF file - 68K
Supplementary Figure S1 from Bone Marrow–Derived Gr1+ Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1
Authors: Catena Raúl , Bhattacharya Nandita , El Rayes Tina , Wang Suming , Choi Hyejin , Gao Dingcheng , Ryu Seongho , Joshi Natasha , Bielenberg Diane , Lee Sharrell B. , Haukaas Svein A. , Gravdal Karsten , Halvorsen Ole J. , Akslen Lars A. , Watnick Randolph S. , Mittal Vivek
Published: April 2023

Supplementary Figure S1 - PDF file 216K, Conditioned media from metastasis-incompetent PC3 cancer cells generate GFP+ CD11b+ BM-derived niches in the lungs
Supplementary Figures S1-S7 from SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
Authors: Furney Simon J. , Pedersen Malin , Gentien David , Dumont Amaury G. , Rapinat Audrey , Desjardins Laurence , Turajlic Samra , Piperno-Neumann Sophie , de la Grange Pierre , Roman-Roman Sergio , Stern Marc-Henri , Marais Richard
Published: April 2023

Supplementary Figures S1-S7 - PDF file 4131K, This file contains Supplementary Figures S1-S7. S1 Summary of somatic copy number alterations in uveal melanoma S2 Circos plots of uveal melanoma genomes S3 Distribution of missense mutations in SF3B1 S4 Kaplan-Meier curves for uveal melanoma patients S5 Alternative splicing in Harbour et al. SF3B1 mutant uveal melanomas S6 qRT-PCR of alternative gene splicing in SF3B1 mutant uveal melanoma S7 SF3B1 mutations Harbour et al. uveal melanomas
Supplementary Figure 2 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1
Authors: Laine Anni , Sihto Harri , Come Christophe , Rosenfeldt Mathias T. , Zwolinska Aleksandra , Niemelä Minna , Khanna Anchit , Chan Edward K. , Kähäri Veli-Matti , Kellokumpu-Lehtinen Pirkko-Liisa , Sansom Owen J. , Evan Gerard I. , Junttila Melissa R. , Ryan Kevin M. , Marine Jean-Christophe , Joensuu Heikki , Westermarck Jukka
Published: April 2023

Supplementary Figure 2 PDF file - 96K, Transcriptional regulation and functional role for CIP2A in response to p53 reactivation
Supplementary Video 2 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
Authors: Taylor Melissa , Billiot Fanny , Marty Virginie , Rouffiac Valérie , Cohen Patrick , Tournay Elodie , Opolon Paule , Louache Fawzia , Vassal Gilles , Laplace-Builhé Corinne , Vielh Philippe , Soria Jean-Charles , Farace Françoise
Published: April 2023

AVI file - 9.8MB
Supplementary Figure 8 from Hypoxia-Dependent Modification of Collagen Networks Promotes Sarcoma Metastasis
Authors: Eisinger-Mathason T.S. Karin , Zhang Minsi , Qiu Qiong , Skuli Nicolas , Nakazawa Michael S. , Karakasheva Tatiana , Mucaj Vera , Shay Jessica E.S. , Stangenberg Lars , Sadri Navid , Puré Ellen , Yoon Sam S. , Kirsch David G. , Simon M. Celeste
Published: April 2023

Supplementary Figure 8 - PDF file 134K, Tumor cells are the major in vivo source of sarcoma collagen
Supplementary Table S2 from Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
Authors: Polkinghorn William R. , Parker Joel S. , Lee Man X. , Kass Elizabeth M. , Spratt Daniel E. , Iaquinta Phillip J. , Arora Vivek K. , Yen Wei-Feng , Cai Ling , Zheng Deyou , Carver Brett S. , Chen Yu , Watson Philip A. , Shah Neel P. , Fujisawa Sho , Goglia Alexander G. , Gopalan Anuradha , Hieronymus Haley , Wongvipat John , Scardino Peter T. , Zelefsky Michael J. , Jasin Maria , Chaudhuri Jayanta , Powell Simon N. , Sawyers Charles L.
Published: April 2023

Supplementary Table S2 - PDF file 250K, Defining AR-regulated DNA repair genes in LNCaP
Supplementary Figure 1 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
Authors: McKie Arthur B. , Vaughan Sebastian , Zanini Elisa , Okon Imoh S. , Louis Louay , de Sousa Camila , Greene Mark I. , Wang Qiang , Agarwal Roshan , Shaposhnikov Dmitry , Wong Joshua L. C. , Gungor Hatice , Janczar Szymon , El-Bahrawy Mona , Lam Eric W-F. , Chayen Naomi E. , Gabra Hani
Published: April 2023

PDF file - 110K
Supplementary Methods, Figure Legends 1-13, Table Legends 1-10 from microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-β Signaling in Glioblastoma
Authors: Genovese Giannicola , Ergun Ayla , Shukla Sachet A. , Campos Benito , Hanna Jason , Ghosh Papia , Quayle Steven N. , Rai Kunal , Colla Simona , Ying Haoqiang , Wu Chang-Jiun , Sarkar Sharmistha , Xiao Yonghong , Zhang Jianhua , Zhang Hailei , Kwong Lawrence , Dunn Katherine , Wiedemeyer Wolf Ruprecht , Brennan Cameron , Zheng Hongwu , Rimm David L. , Collins James J. , Chin Lynda
Published: April 2023

PDF file - 198K
Figure S1 from Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of BrafV600E–Driven Lung Tumors
Authors: Strohecker Anne M. , Guo Jessie Yanxiang , Karsli-Uzunbas Gizem , Price Sandy M. , Chen Guanghua Jim , Mathew Robin , McMahon Martin , White Eileen
Published: April 2023

Figure S1 - PDF file 976K, Persistent deletion of ATG7 in late stage tumorigenesis
Supplementary Methods and References from Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Authors: Montero-Conde Cristina , Ruiz-Llorente Sergio , Dominguez Jose M. , Knauf Jeffrey A. , Viale Agnes , Sherman Eric J. , Ryder Mabel , Ghossein Ronald A. , Rosen Neal , Fagin James A.
Published: April 2023

Supplementary Methods and References PDF File - 39K, Supplementary Methods and References
Supplementary Tables 1-9 from CD36 Repression Activates a Multicellular Stromal Program Shared by High Mammographic Density and Tumor Tissues
Authors: DeFilippis Rosa Anna , Chang Hang , Dumont Nancy , Rabban Joseph T. , Chen Yunn-Yi , Fontenay Gerald V. , Berman Hal K. , Gauthier Mona L. , Zhao Jianxin , Hu Donglei , Marx James J. , Tjoe Judy A. , Ziv Elad , Febbraio Maria , Kerlikowske Karla , Parvin Bahram , Tlsty Thea D.
Published: April 2023

PDF file - 392K, Tables S1, S2, S5, S6, S7 and S8: Patient information Table S3: LDAFs vs HDAFs microarray analysis Table S4: CD36 expression in published microarrays Table S9: Association of CD36 levels with tumor characteristics
Supplementary Methods, Figures 1-10 from Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas
Authors: Taylor Barry S. , DeCarolis Penelope L. , Angeles Christina V. , Brenet Fabienne , Schultz Nikolaus , Antonescu Cristina R. , Scandura Joseph M. , Sander Chris , Viale Agnes J. , Socci Nicholas D. , Singer Samuel
Published: April 2023

PDF file - 960K
Supplementary Figures 1-10, Tables 1-2 from BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
Authors: Faber Anthony C. , Corcoran Ryan B. , Ebi Hiromichi , Sequist Lecia V. , Waltman Belinda A. , Chung Euiheon , Incio Joao , Digumarthy Subba R. , Pollack Sarah F. , Song Youngchul , Muzikansky Alona , Lifshits Eugene , Roberge Sylvie , Coffman Erik J. , Benes Cyril H. , Gómez Henry L. , Baselga José , Arteaga Carlos L. , Rivera Miguel N. , Dias-Santagata Dora , Jain Rakesh K. , Engelman Jeffrey A.
Published: April 2023

PDF file - 21944K
Supplementary Tables 1-2 from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
Authors: Nishimura Masato , Jung Eun-Jung , Shah Maitri Y. , Lu Chunhua , Spizzo Riccardo , Shimizu Masayoshi , Han Hee Dong , Ivan Cristina , Rossi Simona , Zhang Xinna , Nicoloso Milena S. , Wu Sherry Y. , Almeida Maria Ines , Bottsford-Miller Justin , Pecot Chad V. , Zand Behrouz , Matsuo Koji , Shahzad Mian M. , Jennings Nicholas B. , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Calin George A.
Published: April 2023

Supplementary Tables 1-2 - PDF file 85K, MicroRNAs significantly associated with overall survival and response to therapy in ovarian cancer patients using TCGA 2009 database (Table S1) and Clinical and bio-pathological features of the 91 MDACC ovarian cancer samples used in the study (Table S2)
Supplementary Methods and Legends from Antagonism of Inhibitor of Apoptosis Proteins Increases Bone Metastasis via Unexpected Osteoclast Activation
Authors: Yang Chang , Davis Jennifer L. , Zeng Rong , Vora Paras , Su Xinming , Collins Lynne I. , Vangveravong Suwanna , Mach Robert H. , Piwnica-Worms David , Weilbaecher Katherine N. , Faccio Roberta , Veis Novack Deborah
Published: April 2023

PDF file - 175K, Chemical synthesis of 52S and ML183, methods for osteoblast culture, apoptosis and proliferation assays, and real time PCR
Supplementary Figure Legends from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Authors: Bjerke Lynn , Mackay Alan , Nandhabalan Meera , Burford Anna , Jury Alexa , Popov Sergey , Bax Dorine A. , Carvalho Diana , Taylor Kathryn R. , Vinci Maria , Bajrami Ilirjana , McGonnell Imelda M. , Lord Christopher J. , Reis Rui M. , Hargrave Darren , Ashworth Alan , Workman Paul , Jones Chris
Published: April 2023

PDF file - 139K
Supplementary Tables 1-4 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Authors: Guagnano Vito , Kauffmann Audrey , Wöhrle Simon , Stamm Christelle , Ito Moriko , Barys Louise , Pornon Astrid , Yao Yao , Li Fang , Zhang Yun , Chen Zhi , Wilson Christopher J. , Bordas Vincent , Le Douget Mickaël , Gaither L. Alex , Borawski Jason , Monahan John E. , Venkatesan Kavitha , Brümmendorf Thomas , Thomas David M. , Garcia-Echeverria Carlos , Hofmann Francesco , Sellers William R. , Graus-Porta Diana
Published: April 2023

XML file - 99K, Kinase activity and selectivity for NVP-BGJ398; CCLE cell lines sensitive to NVP-BGJ398; GeneSet expression signatures; FGFR genetic alterations and concomitant mutations
Supplementary Figure Legends 1-5 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Authors: Guagnano Vito , Kauffmann Audrey , Wöhrle Simon , Stamm Christelle , Ito Moriko , Barys Louise , Pornon Astrid , Yao Yao , Li Fang , Zhang Yun , Chen Zhi , Wilson Christopher J. , Bordas Vincent , Le Douget Mickaël , Gaither L. Alex , Borawski Jason , Monahan John E. , Venkatesan Kavitha , Brümmendorf Thomas , Thomas David M. , Garcia-Echeverria Carlos , Hofmann Francesco , Sellers William R. , Graus-Porta Diana
Published: April 2023

PDF file - 139K
Supplementary Table 1 from Temporal Dissection of Tumorigenesis in Primary Cancers
Authors: Durinck Steffen , Ho Christine , Wang Nicholas J. , Liao Wilson , Jakkula Lakshmi R. , Collisson Eric A. , Pons Jennifer , Chan Sai-Wing , Lam Ernest T. , Chu Catherine , Park Kyunghee , Hong Sung-woo , Hur Joe S. , Huh Nam , Neuhaus Isaac M. , Yu Siegrid S. , Grekin Roy C. , Mauro Theodora M. , Cleaver James E. , Kwok Pui-Yan , LeBoit Philip E. , Getz Gad , Cibulskis Kristian , Aster Jon C. , Huang Haiyan , Purdom Elizabeth , Li Jian , Bolund Lars , Arron Sarah T. , Gray Joe W. , Spellman Paul T. , Cho Raymond J.
Published: April 2023

Supplementary Table 1 from Temporal Dissection of Tumorigenesis in Primary Cancers
Supplementary Figures S1 - S11 from NOTCH Decoys That Selectively Block DLL/NOTCH or JAG/NOTCH Disrupt Angiogenesis by Unique Mechanisms to Inhibit Tumor Growth
Authors: Kangsamaksin Thaned , Murtomaki Aino , Kofler Natalie M. , Cuervo Henar , Chaudhri Reyhaan A. , Tattersall Ian W. , Rosenstiel Paul E. , Shawber Carrie J. , Kitajewski Jan
Published: April 2023

Figure S1 shows that N11-13 decoy blocks activation of Notch1 by DLL1 but not JAG2 whereas N110-24 decoy blocks activation of Notch1 by JAG2 but not DLL1. Figure S2 shows that purified N11-13 decoy preferentially inhibited DLL4-mediated Notch1 activation, while purified N11-24 decoy inhibited both DLL4 and JAG1-mediated Notch1 activation. Figure S3 shows using co-immunoprecipitation of N1 decoys and soluble versions of DLL4 and JAG1 lacking transmembrane domains that similar ligand specificity of the decoys was observed as when using membrane bound DLL4 or JAG1. Figure S4 shows serum levels of Notch1 decoys in P5 neonatal mice. Figure S5 shows N1 decoys that block JAG disrupted vascular smooth muscle cell association in the actively remodeling neonatal retinal vasculature, but not the mature retinal vasculature. Figure S6 shows that N11-13, N110-24, and N11-24 decoys block soft agar growth of Mm5MT-FGF4 tumor cells but do not affect growth of KP1-VEGF, LLC or B16-F10 tumor lines. Figure S7 shows N1 decoys detected in mouse serum after adenovirus infection and quantification of these levels using ELISA. Figure S8 shows that JAG- inhibiting decoys disrupt vascular smooth muscle coverage in tumors. Figure S9 shows that N1 decoys expressed in mice cause a modest increase of intestinal goblet cells but no significant change in murine weight. Figure S10 shows N1 decoys had no effect on serum markers of liver damage. Figure S11 shows N1 decoys did not affect liver and kidney histopathology.
Supplementary Figure 3 from Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
Authors: Yang Annan , Rajeshkumar N.V. , Wang Xiaoxu , Yabuuchi Shinichi , Alexander Brian M. , Chu Gerald C. , Von Hoff Daniel D. , Maitra Anirban , Kimmelman Alec C.
Published: April 2023

PDF file - 337KB, IHC staining shows absence of Atg5 expression and diminished autophagosomes in tumors with Atg5 deletion.
Supplementary Figure 2 from Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
Authors: Yang Annan , Rajeshkumar N.V. , Wang Xiaoxu , Yabuuchi Shinichi , Alexander Brian M. , Chu Gerald C. , Von Hoff Daniel D. , Maitra Anirban , Kimmelman Alec C.
Published: April 2023

PDF file - 244KB, Deletion of Atg5 in lslKrasG12D, p53L/+, pdxCre+ mice disrupts the exocrine pancreas.
Supplementary Figure 1 from Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
Authors: Yang Annan , Rajeshkumar N.V. , Wang Xiaoxu , Yabuuchi Shinichi , Alexander Brian M. , Chu Gerald C. , Von Hoff Daniel D. , Maitra Anirban , Kimmelman Alec C.
Published: April 2023

PDF file - 181KB, Deletion of Atg5 in pancreata disrupts beta-islets over time.
Supplementary Figure S5 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Authors: Ingle James N. , Liu Mohan , Wickerham D. Lawrence , Schaid Daniel J. , Wang Liewei , Mushiroda Taisei , Kubo Michiaki , Costantino Joseph P. , Vogel Victor G. , Paik Soonmyung , Goetz Matthew P. , Ames Matthew M. , Jenkins Gregory D. , Batzler Anthony , Carlson Erin E. , Flockhart David A. , Wolmark Norman , Nakamura Yusuke , Weinshilboum Richard M.
Published: April 2023

Supplementary Figure S5 - PDF file 147K, ChIP assay for known genotypes of rs6810983 showing functional disruption of an estrogen response element
Supplementary Figure S3 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Authors: Ingle James N. , Liu Mohan , Wickerham D. Lawrence , Schaid Daniel J. , Wang Liewei , Mushiroda Taisei , Kubo Michiaki , Costantino Joseph P. , Vogel Victor G. , Paik Soonmyung , Goetz Matthew P. , Ames Matthew M. , Jenkins Gregory D. , Batzler Anthony , Carlson Erin E. , Flockhart David A. , Wolmark Norman , Nakamura Yusuke , Weinshilboum Richard M.
Published: April 2023

Supplementary Figure S3 - PDF file 93K, ZNF423 and BRCA1 expression in LCLs for variant and wild type genotypes
Supplementary Figure S2 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Authors: Ingle James N. , Liu Mohan , Wickerham D. Lawrence , Schaid Daniel J. , Wang Liewei , Mushiroda Taisei , Kubo Michiaki , Costantino Joseph P. , Vogel Victor G. , Paik Soonmyung , Goetz Matthew P. , Ames Matthew M. , Jenkins Gregory D. , Batzler Anthony , Carlson Erin E. , Flockhart David A. , Wolmark Norman , Nakamura Yusuke , Weinshilboum Richard M.
Published: April 2023

Supplementary Figure S2 - PDF file 17K, ZNF423 expression in two cell lines
Figure S7 from Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity
Authors: Mathew Lijoy K. , Lee Samuel S. , Skuli Nicolas , Rao Shilpa , Keith Brian , Nathanson Katherine L. , Lal Priti , Simon M. Celeste
Published: April 2023

PDF file 311K, Loss of miR-30a-3p promotes UMRC2 tumor growth
Supplementary Figure 5 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
Authors: Pedersen Malin , Küsters-Vandevelde Heidi V.N. , Viros Amaya , Groenen Patricia J.T.A. , Sanchez-Laorden Berta , Gilhuis Jacobus H. , van Engen-van Grunsven Ilse A. , Renier Willy , Schieving Jolanda , Niculescu-Duvaz Ion , Springer Caroline J. , Küsters Benno , Wesseling Pieter , Blokx Willeke A.M. , Marais Richard
Published: April 2023

Supplementary Figure 5 PDF file - 1328K, Histopathology is shown to confirm that the tumors from patients 1 and 2 are melanoma of the CNS and that the congenital nevus from patient 2 expresses NRASQ61K
Supplementary Figure 3 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
Authors: Pedersen Malin , Küsters-Vandevelde Heidi V.N. , Viros Amaya , Groenen Patricia J.T.A. , Sanchez-Laorden Berta , Gilhuis Jacobus H. , van Engen-van Grunsven Ilse A. , Renier Willy , Schieving Jolanda , Niculescu-Duvaz Ion , Springer Caroline J. , Küsters Benno , Wesseling Pieter , Blokx Willeke A.M. , Marais Richard
Published: April 2023

Supplementary Figure 3 PDF file - 498K, Histopathology data are presented to confirm that CNS tumors in our mice are malignant melanomas
Supplementary Figure S5 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Authors: Miao Benchun , Ji Zhenyu , Tan Li , Taylor Michael , Zhang Jianming , Choi Hwan Geun , Frederick Dennie T. , Kumar Raj , Wargo Jennifer A. , Flaherty Keith T. , Gray Nathanael S. , Tsao Hensin
Published: April 2023

Supplementary Figure S5. ALW-II-41-27 suppresses in vivo tumor growth of both VEM sensitive and resistant melanomas.
Supplementary Figure S4 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Authors: Miao Benchun , Ji Zhenyu , Tan Li , Taylor Michael , Zhang Jianming , Choi Hwan Geun , Frederick Dennie T. , Kumar Raj , Wargo Jennifer A. , Flaherty Keith T. , Gray Nathanael S. , Tsao Hensin
Published: April 2023

Supplementary Figure S4. EphA2 inhibitors suppressed the viability of VEM sensitive and resistant BRAF mutant cell lines and NRAS mutant cell lines.
Supplementary Figure S3 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Authors: Miao Benchun , Ji Zhenyu , Tan Li , Taylor Michael , Zhang Jianming , Choi Hwan Geun , Frederick Dennie T. , Kumar Raj , Wargo Jennifer A. , Flaherty Keith T. , Gray Nathanael S. , Tsao Hensin
Published: April 2023

Supplementary Figure S3. Fig. S3. Validation of EphA2 as the target of EphA2 inhibitors.
Supplementary Figures S1-S14 from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
Authors: Malchers Florian , Dietlein Felix , Schöttle Jakob , Lu Xin , Nogova Lucia , Albus Kerstin , Fernandez-Cuesta Lynnette , Heuckmann Johannes M. , Gautschi Oliver , Diebold Joachim , Plenker Dennis , Gardizi Masyar , Scheffler Matthias , Bos Marc , Seidel Danila , Leenders Frauke , Richters André , Peifer Martin , Florin Alexandra , Mainkar Prathama S. , Karre Nagaraju , Chandrasekhar Srivari , George Julie , Silling Steffi , Rauh Daniel , Zander Thomas , Ullrich Roland T. , Reinhardt H. Christian , Ringeisen Francois , Büttner Reinhard , Heukamp Lukas C. , Wolf Jürgen , Thomas Roman K.
Published: April 2023

PDF file 34156K, Table of genes from 16 recurrent amplified genomic regions (Figure S1), amplicon focality on TCGA copy number aberrations (Figure S2), hierarchical clustering of CLCGP copy number data (Figure S3), centrality frequencies of common cancer genes (Figure S4), genotypic cell line annotation (Figure S5), receptor signaling activation of H520 and HCC15 lines (Figure S6), experimental draft for ligand dependency (Figure S7), whole transcriptome analysis FGFR1 splicing (Figure S8), validation of gene expression by qPCR (Figure S9), tumor formation of FGFR1α cells in nude mice (Figure S10), quantification of MYC stains in murine tumor samples (Figure S11), apoptosis is accompanied by cytochrome c release and breakdown of mitochondrial potential (Figure S12), IHC scores of FGFR phosphorylation and MYC expression (Figure S13), High MYC expression identifies a second responder to FGFR inhibitory therapy (Figure S14)
Supplementary Figure S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Authors: Miao Benchun , Ji Zhenyu , Tan Li , Taylor Michael , Zhang Jianming , Choi Hwan Geun , Frederick Dennie T. , Kumar Raj , Wargo Jennifer A. , Flaherty Keith T. , Gray Nathanael S. , Tsao Hensin
Published: April 2023

Supplementary Figure S2. EphA2 inhibitor-kinase interaction maps.